Prognostic value of protein biomarkers in liver transplantation: A systematic review

Proteomics Clin Appl. 2022 Jul;16(4):e2100038. doi: 10.1002/prca.202100038. Epub 2022 Apr 14.

Abstract

Liver transplantation is currently the preferred method for the treatment of advanced liver disease and early-stage hepatocellular carcinoma (HCC). Although advances in surgical techniques, immunosuppressive drugs and postoperative management have reduced the incidence of postoperative complications, how to effectively predict or diagnose postoperative complications earlier and reduce their incidence is still a clinical concern. We performed a comprehensive proteomics literature research to identified protein biomarkers in complications after liver transplantation. Seventeen studies met the inclusion criteria including ischemia reperfusion injury (IRI) (n = 4), acute rejection (AR) (n = 4), renal dysfunction (n = 4), HCC recurrence (n = 2), primary graft dysfunction (PGD) (n = 1), infection (n = 1), and liver fibrosis (n = 1). A total of 625 differentially expressed proteins (DEPs) have been reported between postoperative complications and controls, of which 63 have been validated by quantitative protein expression and 26 have been reported by at least two studies and showed consistently changes. The results of the bioinformation analysis show that the immune system, especially the innate immune system and cytokine signaling in immune system, is an important protein-mediated pathway that affects the prognosis of liver transplantation.

Keywords: biomarkers; diagnostics; pancreato-hepatobiliary system complications; top-down proteomics.

Publication types

  • Review
  • Systematic Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Carcinoma, Hepatocellular*
  • Humans
  • Liver Neoplasms*
  • Liver Transplantation* / adverse effects
  • Liver Transplantation* / methods
  • Postoperative Complications
  • Prognosis

Substances

  • Biomarkers